[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
November 22, 1995

Statement on Use of Apolipoprotein E Testing for Alzheimer Disease

Author Affiliations

Boston (Mass) University (chair); Mt Sinai Medical Center, New York, NY; Emory University, Atlanta, Ga, (ad hoc); Washington University, St Louis, Mo; University of Toronto (Ontario); Columbia University, New York, NY; Boston (Mass) University; Shriver Center, Waltham, Mass; Stanford (Calif) University
From the American College of Medical Genetics, Bethesda, Md.

JAMA. 1995;274(20):1627-1629. doi:10.1001/jama.1995.03530200063039
Abstract

Objective.  —To evaluate the published data on the association between apolipoprotein E genotype (APOE) and Alzheimer disease (AD) and determine whether the data support the use of genetic testing for diagnosis or prediction of disease. This statement is intended for neurologists, psychiatrists, geneticists, primary care providers, diagnostic laboratories, and the public.

Participants.  —The joint American College of Medical Genetics (ACMG) and American Society of Human Genetics (ASHG) Test and Technology Transfer Committee developed a 10-member ACMG/ASHG Working Group to assess available data on the association of AD with APOE alleles. To ensure inclusion of clinical specialists primarily involved with AD patients and families, the American Academy of Neurology (AAN) and the American Psychiatric Association (APA) appointed liaisons to the Working Group.

Evidence.  —Peer-reviewed journal publications obtained from an Index Medicus search or known to members of the Working Group were the source of data on which the statement is based.

Consensus Process.  —Following discussions with all members of the Working Group, a draft statement was prepared by the chair and circulated among all members until a consensus was reached. The consensus draft was sequentially reviewed and endorsed by the appropriate scientific and executive committees of the ACMG, ASHG, AAN, APA, and the National Institutes of Health—Department of Education Working Group on Ethical, Legal, and Social Implications of Human Genome Research. In some instances, suggestions from these committees were incorporated into the final statement.

Conclusions.  —There is general consensus that APOEε4 is strongly associated with AD and that when present may represent an important risk factor for the disease. However, at the present time it is not recommended for use in routine clinical diagnosis nor should it be used for predictive testing. Studies to date indicate that the APOE genotype alone does not provide sufficient sensitivity or specificity to allow genotyping to be used as a diagnostic test. Because AD develops in the absence of APOE ε4 and because many with APOE ε4 seem to escape disease, genotyping is also not recommended for use as a predictive genetic test. The results of a collaborative study under way will clarify some of these issues. Whether APOE genotypes have other uses in the management of AD will become apparent over the next few years.' (JAMA. 1995;274:1627-1629)

References
1.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology . 1984;34:939-945.Article
2.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition . Washington, DC: American Psychiatric Association; 1994.
3.
Risse SC, Raskind MA, Nochlin D, et al.  Neuropathological findings in patients with clinical diagnoses of probable Alzheimer's disease. Am J Psychiatry . 1990;147:168-172.
4.
Joachim CL, Morris JH, Selkoe DJ.  Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann Neurol . 1988;24:50-56.Article
5.
Berg L, Morris JC.  Diagnosis.  In: Terry RD, Katzman R, Bick K, eds. Alzheimer Disease . New York, NY: Raven Press Inc; 1994:9-21.
6.
Mahley RW.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science . 1988;240:622-630.Article
7.
Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ.  Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. JAMA . 1994;272:1666-1671.Article
8.
Saunders AM, Strittmatter WJ, Schmechel D, et al.  Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology . 1993;43:1467-1472.Article
9.
Myers RH, Schaefer EJ, Wilson PWF, et al.  Apolipoprotein E allele 4 is associated with dementia in a population based study: the Framingham Study. Neurology . In press.
10.
Ordovas JM, Litwack-Klein L, Wilson PWF, Schaefer MM, Schaefer EJ.  Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Liped Res . 1987;28:371-380.
11.
Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB.  Interaction of apolipoprotein E genotype, total cholesterol level, and sex in prediction of Alzheimer disease in a case-control study. Neurology . 1995;45:1092-1096.Article
12.
Roses AD.  Apolipoprotein E affects the rate of Alzheimer disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol . 1994;53:429-437.Article
13.
Corder EH, Saunders AM, Strittmatter WJ, et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science . 1993;261:921-923.Article
14.
Corder EH, Saunders AM, Risch NJ, et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet . 1994;7:180-184.Article
15.
Chartier-Harlin M-C, Parfitt M, Legrain S, et al.  Apolipoprotein E, ε4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet . 1994;3:569-574.Article
16.
Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A.  Protection against Alzheimer's disease with apoe e2. Lancet . 1994;343:1432-1433.Article
17.
Smith AD, Johnston C, Sim E, Nagy Z, Jobst KA, Hindley M, King E.  Protective effect of apoE e2 in Alzheimer's disease. Lancet . 1994;344:473-474.
18.
Sorbi S, Nacmias B, Forleo P, et al.  ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease. Neurosci Lett . 1994;177:100-102.Article
19.
van Duijn CM, de Knijff P, Wehnert A, et al.  The apolipoprotein E ε2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol . 1995;37:605-610.Article
20.
Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE.  Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet . 1994;343:1564-1565.Article
21.
Rebeck GW, Perls TT, West HL, Sodhi P, Lipsitz LA, Hyman BT.  Reduced apolipoprotein ε4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology . 1994;44: 1513-1516.Article
22.
Kuusisto J, Koivisto K, Kervinen Mykkänen L, et al.  Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: population based study. BMJ . 1994;309:636-638.Article
23.
Nalbantoglu J, Gilfix BM, Bertrand P, et al.  Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol . 1994;36:889-895.Article
24.
Petersen RC, Smith GE, Ivnik RJ, et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA . 1995;273:1274-1278.Article
25.
Goate A, Chartier-Harlin M-C, Mullan M, et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature . 1991;349:704-706.Article
26.
Sherrington R, Rogaev EI, Liang Y, et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature . 1995;375: 754-760.Article
27.
Levy-Lahad E, Wasco W, Poorkaj P, et al.  Candidate gene for chromosome 1 familial Alzheimer's disease locus. Science . 1995;269:973-977.Article
28.
Pickering-Brown SM, Mann DMA, Bourke JP.  Apolipoprotein ε4 and Alzheimer's disease pathology in Lewy body disease and other amyloid forming diseases. Lancet . 1994;343:1155.Article
29.
Galasko D, Saitoh T, Xia Y, et al.  The apolipoprotein E allele ε4 is overrepresented in patients with the Lewy body variant of Alzheimer disease. Neurology . 1994;44:1950-1951.Article
30.
Betard C, Robitaille Y, Gee M, et al.  Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cerebrovascular disease and vascular dementia. Neuro Report . 1994;5: 1893-1896.
31.
Lippa CF, Smith TW, Saunders AM, et al.  Apolipoprotein E genotype and Lewy body disease. Neurology . 1995;45:97-103.Article
32.
Schneider JA, Gearing M, Robbins RS, de l'Aune W, Mirra SS.  Apolipoprotein E genotype in diverse neurodegenerative disorders. Ann Neurol . 1995;38: 131-135.Article
33.
Farrer LA, Abraham CR, Volicer L, et al.  Allele ε4 of apolipoprotein E shows a dose effect on age at onset of Pick disease. Exp Neurol . In press.
34.
Shimano H, Murase T, Ishibashi S.  Plasma apolipoproteins in patients with multi-infarct dementia. Atherosclerosis . 1989;79:257-260.Article
35.
Frisoni GB, Calabresi L, Geroldi C, et al.  Apolipoprotein E ε4 allele in Alzheimer's disease and vascular dementia. Dementia . 1994;5:240-242.
36.
Kawamata J, Tanaka S, Shimohama S, Ueda K, Kimura J.  Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. J Neurol Neurosurg Psych . 1994;57:1414-1416.Article
37.
Lannfelt L, Lilius L, Nastase M, et al.  Lack of association between apolipoprotein E allele ε4 and sporadic Alzheimer's disease. Neurosci Lett . 1994; 169:175-178.Article
38.
Basun H, Grut M, Winblad B, Lannfelt L.  Apolipoprotein ε4 allele and disease progression in patients with late-onset Alzheimer's disease. Neurosci Lett . 1995;183:32-34.Article
39.
Maestre G, Ottman R, Stern Y, et al.  Apolipoprotein-E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol . 1995;37:254-259.Article
40.
Hendrie HC, Hall KS, Hui S, et al.  Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol . 1995;37:118-120.Article
41.
Davignon J, Gregg RE, Sing CF.  Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis . 1988;8:1-21.Article
42.
Hallman DM, Boerwinkle E, Saha N, et al.  The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet . 1991;49:338-349.
43.
Kamboh MI, Sepehrnia B, Ferrell RE.  Genetic studies of human apolipoproteins, VI: common polymorphism of apolipoprotein E in blacks. Dis Markers . 1989;7:49-55.
44.
Sepehrnia B, Kamboh MI, Adams-Campbell LL, et al.  Genetic studies of human apolipoproteins, X: the effect of apolipoprotein E polymorphism on quantitative levels of lipoproteins in Nigerian blacks. Am J Hum Genet . 1989:45:586-591.
45.
Sandholzer C, Delport R, Vermnaak H, Utermann G.  High frequency of the apo epsilon 4 allele in Khoi San from South Africa. Hum Genet . 1995;95: 46-48.Article
46.
van Duijn CM, de Knijff P, Cruts M, et al.  Apolipoprotein ε4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet . 1994; 7:74-78.Article
47.
Jarvik GP, Wijsman EM.  Alzheimer's disease and the family effect. Nat Genet . 1994;8:115.Article
48.
Farrer LA, Cupples LA, van Duijn CM, et al.  ApoE genotype in patients with Alzheimer disease: implications for the risk of dementia among relatives. Ann Neurol . In press.
49.
Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST.  APOE*4-associated Alzheimer's disease risk is modified by α1-antichymotrypsin polymorphism. Nat Genet . 1995;10:486-488.Article
50.
Okuizumi K, Onodera O, Namba Y, et al.  Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet . 1995;11:207-209.Article
51.
Roses AD.  Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol . 1995;38:6-14.Article
52.
Bird TD.  Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view. Ann Neurol . 1995;38:2-4.Article
53.
van Gool WA, Hijdra A.  Diagnosis of Alzheimer's disease by apolipoprotein E genotyping. Lancet . 1994; 344:275.Article
54.
Farrer LA, Cupples LA, van Duijn CM, Connor-Lacke L, Kiely DK, Growdon JH.  Rate of progression of Alzheimer disease is associated with genetic risk. Arch Neurol . 1995;52:918-923.Article
55.
Corder EH, Saunders AM, Strittmatter WJ, et al.  Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology . 1995;45:1323-1328.Article
×